Vedolizumab SC
Indication
Crohn's disease
Ulcerative colitis
Brand:
Entyvio
Nice TA:
Commissioning responsibility:
CCG
PbR excluded:
Yes
Background
Treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumour necrosis factor-alpha (TNFα) antagonist.
Treatment of adult patients with moderately to severely active Crohn's disease who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumour necrosis factor-alpha (TNFα) antagonist.
The patient and/or carer must receive adequate training in subcutaneous injection technique if their specialist determines that it is appropriate to self-inject and with medical follow-up as necessary. Suitability of the patient for subcutaneous home use should be assessed and patients should be advised to inform their healthcare professional if they experience symptoms of an allergic reaction before administering the next dose. Patients should seek immediate medical attention if developing symptoms of serious allergic reactions.
Also approved for S.C use - see https://www.lancsmmg.nhs.uk/medicines-library/vedolizumab-nice-ta-352/
https://www.lancsmmg.nhs.uk/medicines-library/vedolizumab-nice-ta342/
Recommendation
LSCMMG Recommendation:
Red
Reason for decision:
Specialist medicine